Scarica l'app Stockscreener
5.62
5.05%
0.27
Precedente Chiudi:
$5.35
Aprire:
$5.34
Volume 24 ore:
682.58K
Relative Volume:
0.97
Capitalizzazione di mercato:
$265.38M
Reddito:
-
Utile/perdita netta:
$-238.77M
Rapporto P/E:
-0.2096
EPS:
-26.808
Flusso di cassa netto:
$-216.62M
1 W Prestazione:
+11.73%
1M Prestazione:
+10.85%
6M Prestazione:
-36.50%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.1219
$5.899
Intervallo di 1 settimana:
$4.305
$5.899
Portata 52W:
$3.18
$13.50
Alumis Inc Stock (ALMS) Company Profile
Nome
Alumis Inc
Settore
Industria
Telefono
650-231-6625
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
5.62 | 273.67M | 0 | -238.77M | -216.62M | -26.81 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Iniziato | Oppenheimer | Outperform |
| 2024-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Iniziato | Guggenheim | Buy |
| 2024-07-23 | Iniziato | Leerink Partners | Outperform |
| 2024-07-23 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Alumis Inc Borsa (ALMS) Ultime notizie
Alumis Inc. Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating - marketscreener.com
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (ALMS) ALUMIS INC. Reports Q1 Revenue $17.4M - marketscreener.com
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis wins shareholder nod for ACELYRIN merger - Investing.com Australia
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
ACELYRIN-Alumis Merger Gets Green Light: New Powerhouse in Immune Disease Treatment Emerges - Stock Titan
Barclays PLC Has $193,000 Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Mariner LLC Buys Shares of 18,122 Alumis Inc. (NASDAQ:ALMS) - Defense World
(ALMS) On The My Stocks Page - news.stocktradersdaily.com
Hedge Fund and Insider Trading News: Chris Rokos, Bill Ackman, Ken Griffin, Mario Gabelli, Eisler Capital, Coatue Management, Waratah Capital Advisors, Brevan Howard, Caxton Associates, Alumis Inc (ALMS), Microsoft Corp (MSFT), and More - Insider Monkey
Tuesday’s Top Insider Moves: Alumis Buys Surge, PennyMac Director Sells By Investing.com - Investing.com South Africa
Tuesday’s Top Insider Moves: Alumis Buys Surge, PennyMac Director Sells - Investing.com
Alumis Inc. sees $202,300 stock purchase by Foresite Capital - Investing.com India
Alumis director James Tananbaum acquires $202,300 in stock By Investing.com - Investing.com Canada
Alumis director James Tananbaum acquires $202,300 in stock - Investing.com Australia
Alumis Inc. sees $202,300 in stock purchases by Foresite Labs - Investing.com
Alumis director Srinivas Akkaraju buys shares worth $1.48 million By Investing.com - Investing.com Nigeria
Alumis director Srinivas Akkaraju buys shares worth $1.48 million - Investing.com Australia
ACELYRIN Encourages Stockholders to Support Merger with Alumis Inc. Following ISS Recommendation - Nasdaq
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote 'FOR” the Proposed Transaction with Alumis - The Manila Times
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the ... - Eagle-Tribune
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - Yahoo Finance
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger By Investing.com - Investing.com India
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Investor pressures Acelyrin to exit Alumis merger and liquidate, slams ‘inexplicable’ process - Fierce Biotech
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
Alumis stock price target cut to $14 by H.C. Wainwright - Investing.com Australia
When (ALMS) Moves Investors should Listen - news.stocktradersdaily.com
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis Inc Azioni (ALMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alumis Inc Azioni (ALMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):